MedTrace Logo

Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

NCT00498927 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2016-02-29

Study results available
· View outcomes & findings →

Summary

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with recurrent glioblastoma multiforme or other malignant glioma.

Conditions

Interventions

DRUG

temozolomide

GENETIC

protein expression analysis

GENETIC

reverse transcriptase-polymerase chain reaction

OTHER

diagnostic laboratory biomarker analysis

OTHER

immunoenzyme technique

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Weill Medical College of Cornell University

    collaborator OTHER

  • Schering-Plough

    collaborator INDUSTRY

  • Memorial Sloan Kettering Cancer Center

    lead OTHER

Principal Investigators

  • Antonio Omuro, MD · Memorial Sloan Kettering Cancer Center

  • Thomas Kaley, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00498927 on ClinicalTrials.gov